Showing results (1481-1490 of 1,904) with videos related to

Sort By:
Pageof 191
Blood|February 2, 2012
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activationBethan Psaila, James B Bussel, Matthew D Linden, et al.
The Journal of Clinical Psychiatry|July 13, 1999
Changes in adverse events reported by patients during 6 months of fluoxetine therapyJ Zajecka, J D Amsterdam, F M Quitkin, et al.
The Journal of Rheumatology|December 1, 1994
An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophanD Michelson, S W Page, R Casey, et al.
European Journal of Heart Failure|October 31, 2009
Adherence to medication according to sex and age in the CHARM programmeBradi B Granger, Inger Ekman, Christopher B Granger, et al.
The American Journal of Cardiology|June 5, 1989
Dilevalol compared with propranolol and placebo for systemic hypertensionJ A Schoenberger, W H Frishman, J D Wallin, et al.
JAMA Network Open|May 20, 2026
Hospital and Emergency Department Pediatric Capability, Patient Characteristics, and Radiology Imaging for ChildrenMargaret E Samuels-Kalow, Rebecca E Cash, Kenneth A Michelson, et al.
The Israel Medical Association Journal : IMAJ|April 12, 2026
The Immediate Impact of Hemodialysis on Gait MetricsRelu Cernes, Oded Hershkovich, Tatyana Tsehovsky, et al.
Journal of Thrombosis and Haemostasis : JTH|September 28, 2021
Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet PhysiologyAndrew L Frelinger, José Rivera, David E Connor, et al.
JMIR Research Protocols|September 29, 2021
A Guided Internet-Based Problem-Solving Intervention Delivered Through Smartphones for Secondary School Pupils During the COVID-19 Pandemic in India: Protocol for a Pilot Randomized Controlled TrialPattie P Gonsalves, Rhea Sharma, Eleanor Hodgson, et al.
European Child & Adolescent Psychiatry|March 9, 2006
Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorderPhilip Hazell, Shuyu Zhang, Tomasz Wolańczyk, et al.
Pageof 191